☆ 4.7 Article

Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis

PHARMACEUTICS (2023)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease

Mary E. Rinella et al.

HEPATOLOGY (2023)

Add to Collection

Review Biochemistry & Molecular Biology

GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives

Riccardo Nevola et al.

Summary: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease, affecting 70% of patients with diabetes. There are currently no specific drugs available for its treatment. GLP-1 receptor agonists (GLP-1 RAs) have shown significant impact on body weight and markers of fatty liver and fibrosis in NAFLD patients, in addition to their anti-hyperglycemic effect. This review aims to summarize the available evidence on the role of GLP-1 RAs in NAFLD treatment and propose potential future scenarios.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Review Medicine, General & Internal

Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 16 RCTs

Yan Zhao et al.

Summary: This study aimed to investigate the effects of liraglutide on type 2 diabetes mellitus (T2DM) with nonalcoholic fatty liver disease (NAFLD). Meta-analysis of 16 studies showed that liraglutide can reduce fasting plasma glucose levels, glycosylated hemoglobin A1c levels, triglyceride levels, total cholesterol levels, alanine aminotransferase levels and low-density lipoprotein cholesterol levels in patients, and there are no significant differences in aspartate transaminase and high-density lipoprotein cholesterol levels. However, there are some adverse effects. In conclusion, liraglutide is a potentially curative method for T2DM with NAFLD.

MEDICINE (2023)

Add to Collection

Article Endocrinology & Metabolism

Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study)

Yuka Takahashi et al.

Summary: This study aimed to investigate the effects of switching from liraglutide or dulaglutide to once-weekly semaglutide on glycaemic control and treatment satisfaction in patients with type 2 diabetes. The results showed that the use of once-weekly semaglutide improved glycaemic control and treatment satisfaction. This is a useful treatment option for patients with metabolic abnormalities despite glucagon-like receptor-1 receptor agonist treatment.

DIABETES OBESITY & METABOLISM (2023)

Add to Collection

Article Endocrinology & Metabolism

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022

Summary: The American Diabetes Association's Standards of Medical Care in Diabetes provides clinical practice recommendations and tools to evaluate quality of care. It is updated regularly by a committee of experts.

DIABETES CARE (2022)

Add to Collection

Article Endocrinology & Metabolism

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Melanie J. Davies et al.

Summary: The American Diabetes Association and the European Association for the Study of Diabetes have updated the consensus statements on the management of hyperglycemia in adults with type 2 diabetes. The new recommendations highlight the importance of social determinants of health, weight management, and provide practical tips for implementation.

DIABETES CARE (2022)

Add to Collection

Article Gastroenterology & Hepatology

Dose-response association of the ZJU index and fatty liver disease risk: A large cohort in China

Xue Li et al.

Summary: The study revealed a significant gender-specific association between the ZJU index and the risk of fatty liver disease, emphasizing the importance of maintaining body mass index, alanine aminotransferase, and other factors at normal levels for prevention of fatty liver disease.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease

Arun J. Sanyal et al.

Summary: In this study involving patients with nonalcoholic fatty liver disease, advanced fibrosis stages F3 and F4 were associated with increased risks of liver-related complications and death over a median of 4 years of follow-up. Advanced fibrosis was also related to an increased incidence of liver decompensation events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

Philip N. Newsome et al.

Summary: This phase 2 trial demonstrated that treatment with semaglutide resulted in a significantly higher percentage of patients with NASH resolution compared to placebo in patients with NASH, but did not show a significant between-group difference in the percentage of patients with an improvement in fibrosis stage.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Endocrinology & Metabolism

Prediction and validation of nonalcoholic fatty liver disease by fatty liver index in a Japanese population

Satoko Takahashi et al.

Summary: FLI is a non-invasive predictor of NAFLD, and the cutoff value for Japanese individuals is lower than the original study, showing a significant sex difference between men and women.

ENDOCRINE JOURNAL (2021)

Add to Collection

Article Endocrinology & Metabolism

Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)

M. S. Capehorn et al.

DIABETES & METABOLISM (2020)

Add to Collection

Article Endocrinology & Metabolism

Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)

Mohammad S. Kuchay et al.

DIABETOLOGIA (2020)

Add to Collection

Article Endocrinology & Metabolism

Japanese Clinical Practice Guideline for Diabetes 2019

Eiichi Araki et al.

DIABETOLOGY INTERNATIONAL (2020)

Add to Collection

Article Endocrinology & Metabolism

Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach

Rune V. Overgaard et al.

DIABETES OBESITY & METABOLISM (2019)

Add to Collection

Review Gastroenterology & Hepatology

Current and future pharmacological therapies for NAFLD/NASH

Yoshio Sumida et al.

JOURNAL OF GASTROENTEROLOGY (2018)

Add to Collection

Article Endocrinology & Metabolism

Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme

K. Cusi et al.

DIABETIC MEDICINE (2018)

Add to Collection

Article Endocrinology & Metabolism

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

Richard E. Pratley et al.

LANCET DIABETES & ENDOCRINOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

Matthew James Armstrong et al.

LANCET (2016)

Add to Collection

Article Multidisciplinary Sciences

ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population

Jinghua Wang et al.

SCIENTIFIC REPORTS (2015)

Add to Collection

Article Gastroenterology & Hepatology

Influence of lifestyle-related diseases and age on the development and progression of non-alcoholic fatty liver disease

Toshihide Shima et al.

HEPATOLOGY RESEARCH (2015)

Add to Collection

Review Endocrinology & Metabolism

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

G. Musso et al.

DIABETOLOGIA (2012)

Add to Collection

Article Endocrinology & Metabolism

Histological Course of Nonalcoholic Fatty Liver Disease in Japanese Patients - Tight glycemic control, rather than weight reduction, ameliorates liver fibrosis

Erika Hamaguchi et al.

DIABETES CARE (2010)

Add to Collection

Article Gastroenterology & Hepatology

The impact of visceral fat in nonalcoholic fatty liver disease: cross-sectional and longitudinal studies

Masahiko Koda et al.

JOURNAL OF GASTROENTEROLOGY (2007)

Add to Collection

Article Gastroenterology & Hepatology

The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population

Giorgio Bedogni et al.

BMC GASTROENTEROLOGY (2006)

Add to Collection

Article Gastroenterology & Hepatology

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

Richard K. Sterling et al.

HEPATOLOGY (2006)

Add to Collection

Article Gastroenterology & Hepatology

Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma

HB El-Serag et al.

GASTROENTEROLOGY (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.